毕得医药跌11.15% 2022上市超募8.7亿海通证券保荐

Group 1 - Bid Pharma's stock closed at 47.98 yuan, with a decline of 11.15%, resulting in a total market capitalization of 4.361 billion yuan, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 11, 2022, with an issuance of 16.2291 million shares at a price of 88.00 yuan per share [1] - The total amount raised from the issuance was 1.428 billion yuan, with a net amount of 1.309 billion yuan after deducting issuance costs, exceeding the original plan by 874.6428 million yuan [1] Group 2 - The strategic placement of Bid Pharma's issuance involved participation from the underwriting institution's subsidiaries and a special asset management plan for senior management and core employees [2] - The underwriting institution, Haitong Securities, participated in the strategic placement, acquiring 4.00% of the public offering, amounting to 649,164 shares valued at approximately 57.13 million yuan [2] - The annual profit distribution announced on May 19, 2023, indicated a cash dividend of 1.54 yuan per share and a capital reserve increase of 0.4 shares per share, resulting in a total distribution of approximately 99.97 million yuan and an increase of 25.97 million shares [2]